Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study-Reference-Cited by-同舟云学术

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

Published:2021-03 Issue:3 Volume:2 Page:100135
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Fujimoto Nobukazu,Okada Morihito,Kijima Takashi,Aoe Keisuke,Kato Terufumi,Nakagawa Kazuhiko,Takeda Yuichiro,Hida Toyoaki,Kanai Kuninobu,Hirano Jun,Ohe Yuichiro

Funder

Bristol-Myers Squibb

Ono Pharmaceutical

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference13 articles.

1. Treatment and survival analyses of malignant mesothelioma in Japan;Gemba;Acta Oncol,2013

2. National survey of malignant mesothelioma and asbestos exposure in Japan;Gemba;Cancer Sci,2012

3. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan;Nojiri;Jpn J Clin Oncol,2011

4. National Comprehensive Cancer Network. NCCN guidelines version 1. 2020: Malignant pleural mesothelioma. https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed June 15, 2020.

5. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT);Okada;Clin Cancer Res,2019

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study;Japanese Journal of Clinical Oncology;2024-09-03

2. Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma;Thoracic Cancer;2024-06-05

3. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream;Frontiers in Immunology;2024-01-08

4. New Markers for Management of Mesothelioma;Seminars in Respiratory and Critical Care Medicine;2023-05-30

5. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress;Frontiers in Immunology;2023-01-27